Tempest Therapeutics Files S-8 POS for Employee Stock Plans
Ticker: TPST · Form: S · Filed: Mar 31, 2026 · CIK: 0001544227
| Field | Detail |
|---|---|
| Company | 8 Pos - Tempest Therapeutics, Inc. (TPST) |
| Form Type | S |
| Filed Date | Mar 31, 2026 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: employee-benefits, stock-plan, registration
TL;DR
Tempest Therapeutics just filed to offer stock to employees via benefit plans.
AI Summary
Tempest Therapeutics, Inc. filed an S-8 POS form on March 31, 2026, registering an unspecified number of securities to be offered under its employee benefit plans. This filing indicates the company is making shares available for its employees, likely as part of compensation or incentive programs. The filing does not specify the exact number of shares or the dollar value of the offering.
Why It Matters
This filing allows Tempest Therapeutics to issue stock to employees, which can be a key component of compensation and retention strategies for growing companies.
Risk Assessment
Risk Level: low — An S-8 POS filing is a routine administrative filing related to employee stock plans and does not inherently represent new financial risk.
Key Players & Entities
- Tempest Therapeutics, Inc. (company) — Filer of the S-8 POS
- 0001544227 (company) — CIK number for Tempest Therapeutics, Inc.
- 2026-03-31 (date) — Filing date and effectiveness date
FAQ
What type of filing is this?
This is an S-8 POS filing, which registers securities to be offered to employees in employee benefit plans.
Who is the filer?
The filer is Tempest Therapeutics, Inc., with CIK number 0001544227.
When was the filing made?
The filing was made and accepted on March 31, 2026.
What is the purpose of an S-8 POS filing?
An S-8 POS filing is used by companies to register securities that will be offered to employees under an employee benefit plan.
Does the filing specify the number of shares or dollar amount being offered?
No, the provided filing details do not specify the exact number of shares or the dollar amount of the securities to be offered.
Filing Stats: 957 words · 4 min read · ~3 pages · Grade level 9.8 · Accepted 2026-03-31 06:01:25
Filing Documents
- d90534ds8pos.htm (S-8 POS) — 40KB
- d90534dex232.htm (EX-23.2) — 2KB
- 0001193125-26-133140.txt ( ) — 43KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Brisbane, State of California, on March 31, 2026. Tempest Therapeutics, Inc. By: /s/ Matthew Angel Name: Matthew Angel Title: President and Chief Executive Officer Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated. Signature Title Date /s/ Matthew Angel Matthew Angel President, Chief Executive Officer and Director (Principal Executive Officer) March 31, 2026 /s/ Nicholas Maestas Nicholas Maestas Chief Financial Officer and Head of Corporate Strategy (Principal Financial Officer) March 31, 2026 /s/ Justin Trojanowski Justin Trojanowski Corporate Controller, Treasurer (Principal Accounting Officer) March 31, 2026 * Stephen Brady Chairman of the Board of Directors March 31, 2026 * Christine Pellizzari Director March 31 2026 * Michael Raab Director March 31, 2026 * Ronit Simantov Director March 31, 2026 *By: /s/ Matthew Angel Name: Matthew Angel Attorney-in-fact